Abstract
Introduction
Up to 18% of people in industrialised societies are mildly affected by chronic tinnitus, and 0.5% report tinnitus having a severe effect on their daily life. Tinnitus can be associated with hearing loss, acoustic neuromas, drug toxicity, ear diseases, and depression. Tinnitus can last for many years, and can interfere with sleep and concentration.
Methods and outcomes
We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for chronic tinnitus? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2011 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Results
We found 29 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
Conclusions
In this systematic review, we present information relating to the effectiveness and safety of the following interventions: acamprosate, acupuncture, antidepressant drugs, benzodiazepines, carbamazepine, cinnarizine, electromagnetic stimulation, ginkgo biloba, hearing aids, hypnosis, psychotherapy, tinnitus-masking devices, and tinnitus retraining therapy.
Key Points
Up to 18% of people in industrialised societies are mildly affected by chronic tinnitus, and 0.5% report tinnitus having a severe effect on their daily life.
Tinnitus can be associated with hearing loss, acoustic neuromas, drug toxicity, ear diseases, or depression.
Tinnitus can last for many years, and can interfere with sleep and concentration.
There is insufficient evidence to show that antidepressant drugs improve tinnitus symptoms.
Antidepressant drugs can improve depression in people with tinnitus.
Tricyclic antidepressants (TCAs) are associated with adverse effects such as dry mouth, blurred vision, and constipation.
CBT may be ineffective at reducing tinnitus loudness, but it may improve quality of life in people with tinnitus.
We don't know whether benzodiazepines, acupuncture, hypnosis, electromagnetic stimulation, hearing aids, tinnitus-masking devices, tinnitus retraining therapy, cinnarizine, ginkgo biloba, or acamprosate are effective in people with tinnitus, as we found few studies.
Carbamazepine may be no more effective than placebo at improving symptoms of tinnitus, and is associated with adverse effects such as dizziness, nausea, and headache.
About this condition
Definition
Tinnitus is the perception of sound in the ear or head that does not arise from the external environment, from within the body (e.g., vascular sounds), or from auditory hallucinations related to mental illness. This review is concerned with tinnitus for which tinnitus is the only, or the predominant, symptom in an affected person.
Incidence/ Prevalence
Up to 18% of the general population in industrialised countries are mildly affected by chronic tinnitus, and 0.5% report tinnitus having a severe effect on their ability to lead a normal life.
Aetiology/ Risk factors
Tinnitus can occur as an isolated idiopathic symptom, or in association with any type of hearing loss. Tinnitus can be a particular feature of presbycusis (age-related hearing loss), noise-induced hearing loss, Menière's disease (see review on Menière's disease), or the presence of an acoustic neuroma. In people with toxicity from aspirin or quinine, tinnitus can occur with hearing thresholds remaining normal. Tinnitus is also associated with depression, although it can be unclear whether the tinnitus is a manifestation of the depressive illness or a factor contributing to its development. Studies involving people with tinnitus caused by Menière's disease, acoustic neuroma, chronic otitis media, head injury, barotraumas, or other clear pathology have been excluded from this review. This review is principally concerned with idiopathic tinnitus with or without degenerative sensorineural hearing loss.
Prognosis
Tinnitus can have an insidious onset, with a long delay before clinical presentation. It can persist for many years or decades, particularly when associated with a sensorineural hearing loss. Tinnitus can cause disruption of sleep patterns, an inability to concentrate, and depression.
Aims of intervention
To reduce the loudness and intrusiveness of the tinnitus, and to reduce its impact on daily life, with minimum adverse effects of treatment.
Outcomes
Resolution of tinnitus; improvement in tinnitus (includes tinnitus loudness [assessed by a visual analogue scale or symptom scores]); impact of tinnitus on quality of life, as measured by estimates of interference with activities of daily life or with emotional state; and adverse effects of treatment.
Methods
Clinical Evidence search and appraisal July 2011. The following databases were used to identify studies for this systematic review: Medline 1966 to July 2011, Embase 1980 to July 2011, and The Cochrane Database of Systematic Reviews 2011, Issue 2 (1966 to date of issue). An additional search within The Cochrane Library was carried out for the Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA). We also searched for retractions of studies included in the review. Abstracts of the studies retrieved from the initial search were assessed by an information specialist. Selected studies were then sent to the contributor for additional assessment, using predetermined criteria to identify relevant studies. Study design criteria for inclusion in this review were: published systematic reviews of RCTs and RCTs in any language, at least single blinded, and containing >20 individuals of whom >80% were followed up. There was no minimum length of follow-up required to include studies. We excluded all studies described as "open", "open label", or not blinded unless blinding was impossible. We included systematic reviews of RCTs and RCTs where harms of an included intervention were studied applying the same study design criteria for inclusion as we did for benefits. In addition we did an observational harms search for specific harms as highlighted by the contributor, peer reviewer, and editor. In addition we use a regular surveillance protocol to capture harms alerts from organisations such as the FDA and the MHRA, which are added to the reviews as required. To aid readability of the numerical data in our reviews, we round many percentages to the nearest whole number. Readers should be aware of this when relating percentages to summary statistics such as relative risks (RRs) and odds ratios (ORs). We have performed a GRADE evaluation of the quality of evidence for interventions included in this review (see table). The categorisation of the quality of the evidence (high, moderate, low, or very low) reflects the quality of evidence available for our chosen outcomes in our defined populations of interest. These categorisations are not necessarily a reflection of the overall methodological quality of any individual study, because the Clinical Evidence population and outcome of choice may represent only a small subset of the total outcomes reported, and population included, in any individual trial. For further details of how we perform the GRADE evaluation and the scoring system we use, please see our website (www.clinicalevidence.com).
Table.
GRADE Evaluation of interventions for Tinnitus.
| Important outcomes | Impact of tinnitus on quality of life, Improvement in tinnitus, Resolution of tinnitus | ||||||||
| Studies (Participants) | Outcome | Comparison | Type of evidence | Quality | Consistency | Directness | Effect size | GRADE | Comment |
| What are the effects of treatments for chronic tinnitus? | |||||||||
| 1 (50) | Improvement in tinnitus | Acamprosate versus placebo | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and no intention-to-treat analysis |
| 3 (122) | Improvement in tinnitus | Acupuncture versus sham acupuncture | 4 | –2 | –1 | 0 | 0 | Very low | Quality points deducted for sparse data and incomplete reporting of results. Consistency point deducted for conflicting results |
| 1 (54) | Impact of tinnitus on quality of life | Acupuncture versus sham acupuncture | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and incomplete reporting of results |
| 4 (405) | Improvement in tinnitus | Tricyclic antidepressants (TCAs) versus placebo | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for incomplete reporting of results |
| 1 (117) | Impact of tinnitus on quality of life | Tricyclic antidepressants (TCAs) versus placebo | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and incomplete reporting of results |
| 2 (196) | Improvement in tinnitus | SSRIs versus placebo | 4 | –1 | 0 | –1 | 0 | Low | Quality point deducted for sparse data. Directness point deducted for inclusion of a co-intervention in 1 RCT (oxazepam) |
| 1 (76) | Impact of tinnitus on quality of life | SSRIs versus placebo | 4 | –2 | 0 | –1 | 0 | Very low | Quality points deducted for sparse data and RCT being underpowered to detect a clinically meaningful difference between groups. Directness point deducted for inclusion of a co-intervention (oxazepam) |
| 2 (70) | Improvement in tinnitus | Benzodiazepines versus placebo | 4 | –3 | 0 | –1 | 0 | Very low | Quality points deducted for sparse data, incomplete reporting of results, and flaws with blinding in 1 RCT. Directness point deducted for lack of inert placebo in crossover RCT |
| 1 (30) | Improvement in tinnitus | Cinnarizine versus placebo | 4 | –3 | 0 | 0 | 0 | Very low | Quality points deducted for sparse data, incomplete reporting of results, and uncertain follow-up |
| 2 (78) | Improvement in tinnitus | Electromagnetic stimulation versus placebo | 4 | –3 | –1 | 0 | 0 | Very low | Quality points deducted for sparse data, incomplete reporting of results, and other methodological flaws. Consistency point deducted for conflicting results |
| 1 (66) | Improvement in tinnitus | Ginkgo biloba versus placebo | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for sparse data |
| 1 (39) | Improvement in tinnitus | Hearing aids versus waiting list control | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and incomplete reporting of results |
| 1 (92) | Improvement in tinnitus | Hypnosis versus counselling | 4 | –2 | 0 | –1 | 0 | Very low | Quality points deducted for sparse data and incomplete reporting of results. Directness point deducted for inclusion of only those who were suggestible to hypnosis |
| 18 (787) | Improvement in tinnitus | CBT versus placebo | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for methodological flaws of 1 review |
| at least 9 (at least 455) | Impact of tinnitus on quality of life | CBT versus placebo | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for methodological flaws of 1 review |
| 1 (21) | Improvement in tinnitus | Tinnitus-masking devices versus placebo | 4 | –3 | 0 | 0 | 0 | Very low | Quality points deducted for sparse data, no blinding, incomplete reporting of results, and other methodological flaws (reporting of post-crossover results) |
| 1 (48) | Improvement in tinnitus | Carbamazepine versus placebo | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and incomplete reporting of results |
We initially allocate 4 points to evidence from RCTs, and 2 points to evidence from observational studies. To attain the final GRADE score for a given comparison, points are deducted or added from this initial score based on preset criteria relating to the categories of quality, directness, consistency, and effect size. Quality: based on issues affecting methodological rigour (e.g., incomplete reporting of results, quasi-randomisation, sparse data [<200 people in the analysis]). Consistency: based on similarity of results across studies. Directness: based on generalisability of population or outcomes. Effect size: based on magnitude of effect as measured by statistics such as relative risk, odds ratio, or hazard ratio.
Glossary
- Low-quality evidence
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- Masking device
A small device similar to a behind-the-ear hearing aid that produces a broad frequency noise. It is thought to hide the noise of the tinnitus.
- Menière's disease
A condition characterised by episodic vertigo, tinnitus, and sensorineural hearing loss.
- Moderate-quality evidence
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- Presbycusis
Age-related hearing loss.
- Tinnitus Handicap Inventory
A questionnaire assessing the impact of tinnitus on the subject's quality of life.
- Tinnitus retraining therapy
A combination of cognitive behavioural therapy and tinnitus masking, highly tailored to individual people.
- Very low-quality evidence
Any estimate of effect is very uncertain.
Contributor Information
Julian Savage, Southmead Hospital, Bristol, UK.
Angus Waddell, Great Western Hospital, Swindon, UK.
References
- 1.Coles RR. Epidemiology of tinnitus: (1) prevalence. J Laryngol Otol 1984;9(suppl):7–15. [DOI] [PubMed] [Google Scholar]
- 2.Sullivan MD, Katon W, Dobie R, et al. Disabling tinnitus: association with affective disorder. Gen Hosp Psychiatry 1988;10:285–291. [DOI] [PubMed] [Google Scholar]
- 3.Zoger S, Svedlund J, Holgers KM. Psychiatric disorders in tinnitus patients without severe hearing impairment: 24 month follow-up of patients at an audiological clinic. Audiology 2001;40:133–140. [DOI] [PubMed] [Google Scholar]
- 4.Azevedo AA, Figueiredo RR. Tinnitus treatment with acamprosate: double-blind study. Rev Bras Otorhinolaringol 2005;71:618–623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Park J, White AR, Ernst E. Efficacy of acupuncture as a treatment for tinnitus: a systematic review. Arch Otolaryngol Head Neck Surg 2000;126:489–492. Search date 1998. [DOI] [PubMed] [Google Scholar]
- 6.Axelsson A, Andersson S, Gu LD. Acupuncture in the management of tinnitus: a placebo-controlled study. Audiology 1994;33:351–360. [DOI] [PubMed] [Google Scholar]
- 7.Podoshin L, Ben-David Y, Fradis M, et al. Idiopathic subjective tinnitus treated by biofeedback, acupuncture and drug therapy. Ear Nose Throat J 1991;70:284–289. [PubMed] [Google Scholar]
- 8.Furugard S, Hedin PJ, Eggertz A, et al. Acupuncture worth trying in severe tinnitus. Lakartidningen 1998;95:1922–1928. [In Swedish] [PubMed] [Google Scholar]
- 9.Marks NJ, Emery P, Onisiphorou C. A controlled trial of acupuncture in tinnitus. J Laryngol Otol 1984;98:1103–1109. [DOI] [PubMed] [Google Scholar]
- 10.Hansen PE, Hansen JH, Bentzen O. Acupuncture therapy of chronic unilateral tinnitus. A double-blind cross-over study. Ugeskr Laeger 1981;143:2888–2890. [In Danish] [PubMed] [Google Scholar]
- 11.Vilholm OJ, Moller K, Jorgensen K. Effect of traditional Chinese acupuncture on severe tinnitus: a double-blind, placebo-controlled, clinical investigation with open therapeutic control. Br J Audiol 1998;32:197–204. [DOI] [PubMed] [Google Scholar]
- 12.Baldo P, Doree C, Lazzarini R, et al. Antidepressants for patients with tinnitus. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2008. 17054188 [Google Scholar]
- 13.Bayar N, Boke B, Turan E, et al. Efficacy of amitriptyline in the treatment of subjective tinnitus. J Otolaryngol 2001;30:300–303. [DOI] [PubMed] [Google Scholar]
- 14.Mihail RC, Crowley JM, Walden BE, et al. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otolo Rhinol Laryngol 1988;97:120–123. [DOI] [PubMed] [Google Scholar]
- 15.Podoshin L, Ben-David Y, Fradis M, et al. Idiopathic subjective tinnitus treated by amitryptiline hydrochloride/biofeedback. Int Tinnitus J 1995;1:54–60. [PubMed] [Google Scholar]
- 16.Sullivan M, Katon W, Russo J, et al. A randomised trial of nortriptyline for severe chronic tinnitus. Arch Intern Med 1993;153:2251–2259. [PubMed] [Google Scholar]
- 17.Robinson SK, Viirre ES, Bailey KA, et al. Randomised placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 2005;67:981–988. [DOI] [PubMed] [Google Scholar]
- 18.Zoger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering - a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2006;26:32–39. [DOI] [PubMed] [Google Scholar]
- 19.Holgers KM, Zoger S, Svedlund J. The impact of sertraline on health-related quality of life in severe refractory tinnitus: a double-blind, randomized, placebo-controlled study. Audiol Med 2011;9:67–72. [Google Scholar]
- 20.Schilter B, Jager B, Heerman R, et al. Pharmacological and psychological treatment options in chronic subjective tinnitus: a meta-analysis of effective treatments. HNO 2000;48:589–597. Search date 1995. [DOI] [PubMed] [Google Scholar]
- 21.Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg 1993;119:842–845. [DOI] [PubMed] [Google Scholar]
- 22.Jalali MM, Kousha A, Naghavi SE, et al. The effects of alprazolam on tinnitus: a cross-over randomized clinical trial. Med Sci Monit 2009;15:I55–I60. [PubMed] [Google Scholar]
- 23.Dobie RA. A review of randomized clinical trials in tinnitus. Laryngoscope 1999;109:1202–1211. Search date 1998. [DOI] [PubMed] [Google Scholar]
- 24.Roland NJ, Hughes JB, Daley MB, et al. Electromagnetic stimulation as a treatment of tinnitus: a pilot study. Clin Otolaryngol 1993;18:278–281. [DOI] [PubMed] [Google Scholar]
- 25.Dobie RA, Hoberg KE, Rees TS. Electrical tinnitus suppression: a double-blind crossover study. Otolaryngol Head Neck Surg 1986;95:319–333. [DOI] [PubMed] [Google Scholar]
- 26.Hilton M, Stuart E. Ginkgo biloba for tinnitus. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2009. [Google Scholar]
- 27.Morgenstern C, Biermann E. Long-term treatment of tinnitus with the special gingko extract, Egb 761. Fortschr Med 1997;115:57–58. [In German] [Google Scholar]
- 28.Drew S, Davies E. Effectiveness of ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. BMJ 2001;322:73–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Rejali D, Sivakumar A, Balaji N. Ginkgo biloba does not benefit patients with tinnitus: a randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol Allied Sci 2004;29:226–231. [DOI] [PubMed] [Google Scholar]
- 30.Melin L, Scott B, Lindberg P, et al. Hearing aids and tinnitus – an experimental group study. Br J Audiol 1987;21:91–97. [DOI] [PubMed] [Google Scholar]
- 31.Mason JD, Rogerson DR, Butler JD. Client centred hypnotherapy in the management of tinnitus — is it better than counselling? J Laryngol Otol 1996;110:117–120. [DOI] [PubMed] [Google Scholar]
- 32.Martinez Devesa P, Waddell A, Perera R, et al. Cognitive behavioural therapy for tinnitus. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2010. 20824844 [Google Scholar]
- 33.Andersson G, Lyttkens L. A meta-analytic review of psychological treatments for tinnitus. Br J Audiol 1999;33:201–210. Search date 1998. [DOI] [PubMed] [Google Scholar]
- 34.Stephens SDG, Corcoran AL. A controlled study of tinnitus masking. Br J Audiol 1985;19:159–167. [DOI] [PubMed] [Google Scholar]
- 35.Erlandsson S, Ringdahl A, Hutchins T, et al. Treatment of tinnitus: a controlled comparison of masking and placebo. Br J Audiol 1987;21:37–44. [DOI] [PubMed] [Google Scholar]
- 36.Hulshof JH, Vermeij P. The value of carbamazepine in the treatment of tinnitus. ORL J Otorhinolaryngol Relat Spec 1985;47:262–266. [DOI] [PubMed] [Google Scholar]